<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03129685</url>
  </required_header>
  <id_info>
    <org_study_id>IS-001-17</org_study_id>
    <nct_id>NCT03129685</nct_id>
  </id_info>
  <brief_title>Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma</brief_title>
  <acronym>NRU</acronym>
  <official_title>Short-term Outcome of Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The National Ribat University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The National Ribat University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of short-term outcomes of ipsilateral lobe arterial devascularization of the large
      hepatocellular carcinoma: single center non-randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the 30-day mortality and major complications as well as the tumor size changes
      of the patients undergoing ipsilateral lobe arterial devascularization of the large
      hepatocellular carcinoma. This is a prospective non randomized trial carried out at the Ribat
      University Hospital between April 2017 to March 2018.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2017</start_date>
  <completion_date type="Anticipated">July 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 19, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective and non-randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short term mortality rate</measure>
    <time_frame>30 day</time_frame>
    <description>Percentage of patients` postoperative deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short term major complications` rate</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of Clavien/Dindo grade 3 or more postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor size change rate</measure>
    <time_frame>30 days</time_frame>
    <description>Mean percentage change in the sizes of the patients` tumors</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Devascularization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing ipsilateral liver lobe arterial devascularization (ILAD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ILAD</intervention_name>
    <description>This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.</description>
    <arm_group_label>Devascularization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Review and sign informed consent;

          -  Between 15 and 80 years of age at time of trial enrollment;

          -  Documented pathological and/or radiological diagnosis of hepatocellular carcinoma;

          -  Radiologically documented tumor size of &gt; 5 centimeters;

          -  Radiologically documented liver cirrhosis.

        Exclusion Criteria:

          -  American Anesthesia Association (ASA) Class IV or V and/or any contraindications to
             general anesthesia;

          -  Uncontrollable ascites;

          -  Deep persistent jaundice;

          -  Hepatic encephalopathy;

          -  Coagulopathy;

          -  Severe thrombocytopenia;

          -  Unable or unwilling to attend follow up visits and examinations;

          -  Other associated surgical procedure;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama M Elsanousi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine. The National Ribat University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Osama M Elsanousi, MD</last_name>
    <phone>+249 1222 29574</phone>
    <email>osamagreen55@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ribat University Hospital</name>
      <address>
        <city>Khartoum</city>
        <zip>11111</zip>
        <country>Sudan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>September 24, 2017</last_update_submitted>
  <last_update_submitted_qc>September 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The National Ribat University</investigator_affiliation>
    <investigator_full_name>Osama Mohamed Elsanousi</investigator_full_name>
    <investigator_title>Associate Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Devascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

